About Speratum Biopharma, Inc.
Speratum is a pre-clinical stage biotechnology company focused on research and development of targeted molecular therapeutics based on core technologies exclusively licensed from Baylor College of Medicine. Speratum’s platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities.

Speratum is currently in advance pre-clinical stages of development for its lead therapeutic candidate, a small RNA tumor suppressor in several solid cancer.

For more information about Speratum Biopharma, please e-mail info@speratum.com


Speratum Biopharma is comprised of a team of talented scientists, clinicians, and executives committed to developing breakthrough science from bench to bedside.


Christian Marín-Müller

MS - PhD

Founder and Chief Executive Officer
Co-inventor of Speratum’s technologies


Osvaldo Vega-Martínez


Chief Science Officer
Co-inventor of Speratum’s technologies


Allan Boruchowicz


Founder and Managing
Director Carao Ventures


Speratum Biopharma, Inc. is an innovative biotechnology company focused on pre-clinical research and development of oligonucleotide therapeutics for the treatment of cancer. The company’s primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of miR-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids.

See our Publications